(Q38592767)

4 September 2017

title

Nonalcoholic fatty liver disease - current status and future directions (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

4 September 2017

1 reference

1 reference

1 reference

Münevver Demir

1

1 reference

4 September 2017

Sonja Lang

series ordinal

2

1 reference

4 September 2017

Hans-Michael Steffen

series ordinal

3

1 reference

4 September 2017

publication date

25 September 2015

1 reference

Journal of Digestive Diseases

4 September 2017

published in

1 reference

4 September 2017

volume

16

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

541-557

1 reference

Nonalcoholic fatty liver disease: pathology and pathogenesis

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

NAFLD, NASH and liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Evolving therapies for non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Human nutrition, the gut microbiome and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Non-alcoholic steatohepatitis: a microbiota-driven disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Pharmacological agents for NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Epidemiology and natural history of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Epidemiology of non-alcoholic fatty liver disease in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Population-based risk factors and resource utilization for HCC: US perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Clinical trial watch: reports from the AASLD Liver Meeting®, Boston, November 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Characterization of metabolically unhealthy normal-weight individuals: Risk factors and their associations with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Roles for chemokines in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

21 January 2018

The genetics of NAFLD.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Management and diagnosis of fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

From NAFLD in clinical practice to answers from guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The Framingham risk score and heart disease in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Prediction of first coronary events with the Framingham score: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Dietary fructose in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Gut microbiome and nonalcoholic fatty liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The Gordian Knot of dysbiosis, obesity and NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Pathogenesis of steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Linking intestinal homeostasis and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Immune and inflammatory pathways in NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Vitamin E deficiency induces liver nuclear factor-kappaB DNA-binding activity and changes in related genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Targeting bile-acid signalling for metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Nonalcoholic fatty liver disease: new treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12291

21 January 2018

Identifiers

DOI

10.1111/1751-2980.12291

1 reference

4 September 2017

1 reference